Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03190473Not ApplicableTerminated

OPTIMIZE IDE for the Treatment of ACS

Role: lead

NCT01788150Not ApplicableCompleted

Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System

Role: lead

NCT03716102Not ApplicableActive Not Recruiting

OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study

Role: lead

NCT02693158Completed

The Direct III Post Market Study

Role: lead

All 4 trials loaded